Back to search

Article

Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns

2026-04-16

Abstract excerpt

Semaglutide has shown benefit in metabolic dysfunction-associated steatohepatitis (MASH), but real-world evidence across longitudinal liver phenotypes remains limited, particularly regarding how liver remodeling relates to weight loss and dose exposure. Using a de-identified federated electronic health record network spanning more than 29 million patients in the United States, including 489,785 semaglutide-treated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
df21393c-4787-59d1-8d17-c23e5b2ca415
DOI
10.64898/2026.04.14.26350891
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patternsDOI 10.64898/2026.04.14.26350891
Association of Antihypertensive Medication and Steatotic Liver Disease with Liver Fibrosis and Mortality among US AdultsSemantic proximity
Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case-control studySemantic proximity
Combined Semaglutide and Exercise Ameliorate HFpEF-Associated MASH: Multi-Omics InsightsSemantic proximity
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events.Semantic proximity
Proton Pump Inhibitors Use is Associated with Increased Liver Steatosis: A Nationally Representative StudySemantic proximity
Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer PanelsSemantic proximity
An 8-Week Very Low-Calorie Ketogenic Diet (VLCKD) Alters the Landscape of Obese-Derived Small Extracellular Vesicles (sEVs), Redefining Hepatic Cell Phenotypes.Semantic proximity
Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population.Semantic proximity
Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lostSemantic proximity
GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASHSemantic proximity
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
Influence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studySemantic proximity
Select a neighboring publication to make it the new centre.